Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years
Publication
, Journal Article
Farnier, M; Colhoun, HM; Sasiela, WJ; Edelberg, JM; Asset, G; Robinson, JG
Published in: Journal of Clinical Lipidology
July 2017
Duke Scholars
Published In
Journal of Clinical Lipidology
DOI
ISSN
1933-2874
Publication Date
July 2017
Volume
11
Issue
4
Start / End Page
986 / 997
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3205 Medical biochemistry and metabolomics
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Farnier, M., Colhoun, H. M., Sasiela, W. J., Edelberg, J. M., Asset, G., & Robinson, J. G. (2017). Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. Journal of Clinical Lipidology, 11(4), 986–997. https://doi.org/10.1016/j.jacl.2017.05.016
Farnier, Michel, Helen M. Colhoun, William J. Sasiela, Jay M. Edelberg, Gaëlle Asset, and Jennifer G. Robinson. “Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years.” Journal of Clinical Lipidology 11, no. 4 (July 2017): 986–97. https://doi.org/10.1016/j.jacl.2017.05.016.
Farnier M, Colhoun HM, Sasiela WJ, Edelberg JM, Asset G, Robinson JG. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. Journal of Clinical Lipidology. 2017 Jul;11(4):986–97.
Farnier, Michel, et al. “Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years.” Journal of Clinical Lipidology, vol. 11, no. 4, Elsevier BV, July 2017, pp. 986–97. Crossref, doi:10.1016/j.jacl.2017.05.016.
Farnier M, Colhoun HM, Sasiela WJ, Edelberg JM, Asset G, Robinson JG. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. Journal of Clinical Lipidology. Elsevier BV; 2017 Jul;11(4):986–997.
Published In
Journal of Clinical Lipidology
DOI
ISSN
1933-2874
Publication Date
July 2017
Volume
11
Issue
4
Start / End Page
986 / 997
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3205 Medical biochemistry and metabolomics
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
- 1101 Medical Biochemistry and Metabolomics